BioSyent Inc. (CVE:RX) Insider Sells C$2,566,496.00 in Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 230,800 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Price Performance

RX stock traded up C$0.45 during mid-day trading on Monday, reaching C$11.70. The company’s stock had a trading volume of 5,017 shares, compared to its average volume of 6,849. The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. The company’s 50 day moving average is C$11.05 and its two-hundred day moving average is C$10.27. BioSyent Inc. has a fifty-two week low of C$8.24 and a fifty-two week high of C$11.74. The stock has a market cap of C$135.60 million, a PE ratio of 19.50 and a beta of 0.93.

BioSyent (CVE:RX) last posted its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C$0.13. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. The business had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. Equities research analysts expect that BioSyent Inc. will post 0.6944444 EPS for the current year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.